Using patient-derived CML CD34+ cells we examined the effect of imatinib on TCA cycle substrates: glucose, palmitate, and glutamine as well as on their contribution to the TCA cycle intermediates. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.